500X Increase In Compute Performance Scalable Compute & Memory Packaging & Interconnect For Density & Scale Full Software Stack/Programming Model

Abstract Among 9,048 people infected with SARS-CoV-2 between January-May, 2021 in Maryland, in regression-adjusted analysis, SARS-CoV-2 viruses carrying the spike protein mutation E484K were disproportionately prevalent among persons infected after full vaccination against COVID-19 as compared to infected persons who were not fully vaccinated (aOR 1.96, 95% CI, 1.36 to 2.83).

This article consists only of a collection of slides from the author's conference presentation.

This article describes and contrasts the public health response to two human rabies cases: one organ recipient diagnosed within days of symptom onset and the transplant donor who was diagnosed 18 months post-symptom onset. In response to an organ-transplant-related rabies case diagnosed in 2013, organ donor and recipient investigations were conducted by multiple public health agencies. Persons with potential exposure to infectious patient materials were assessed for rabies virus exposure. An exposure investigation was conducted to determine the source of the organ donor's infection. Over 100 persons from more than 20 agencies spent over 2700 h conducting contact investigations in healthcare, military and community settings. The 564 persons assessed include 417 healthcare workers [5.8% recommended for post-exposure prophylaxis (PEP)], 96 community contacts (15.6% recommended for PEP), 30 autopsy personnel (50% recommended for PEP), and 21 other persons (4.8% recommended for PEP). Donor contacts represented 188 assessed with 20.2% recommended for PEP, compared with 5.6% of 306 recipient contacts recommended for PEP. Human rabies cases result in substantial use of public health and medical resources, especially when diagnosis is delayed. Although rare, clinicians should consider rabies in cases of encephalitis of unexplained aetiology, particularly for cases that may result in organ donation.

Computing is evolving as smartphones and tablets increasingly become primary entertainment devices. This shift requires greater performance from mobile processors to deliver the same quality experiences that a PC or gaming console does, but without compromising battery life in a more compact mobile device form factor. The mobile GPU is offers tremendous computing potential to enable unprecedented experiences from vision for augmented reality, to game physics, geometry creation and image processing. This panel, composed of leading mobile graphics experts from Qualcomm, ARM, Google, Intel, Lytro and Pelican Imaging will cover the newest and best ways advanced programmers can take advantage of the massive computing power of today's mobile GPUs. The discussion will cover the GPU and system architectures, as well as compute APIs like OpenCL and Renderscript to enable GPGPU. The panel will address the opportunities and challenges of GPU compute, the architecture required to support it, and their vision for where it will take us. Designed for advanced programmers, as well as thought leaders in the industry, attendees will leave this session with a clear understanding of the latest developments in mobile GPU compute. Beyond what is possible today, industry experts on this panel will explore where mobile graphics are headed and discuss their companies' respective visions for the future of mobile compute. Attendees will have an opportunity at the end of the panel to pose questions.

Computing is evolving as smartphones and tablets increasingly become primary entertainment devices. This shift requires greater performance from mobile processors to deliver the same quality experiences that a PC or gaming console does, but without compromising battery life in a more compact mobile device form factor. This panel, composed of leading mobile graphics experts from Qualcomm, NVIDIA, Intel, ARM and Imagination Technologies, will cover the newest and best ways advanced programmers can take advantage of GPU design implementation and optimize for mobile-specific platforms. The discussion will cover the latest graphics APIs like OpenGL ES 3.0 for sophisticated graphics programming, compute APIs like OpenCL to enable GPGPU acceleration, and Android APIs like Renderscript for advanced features such as instancing, occlusion queries, superior texture compression formats, and multiple render targets. Panelists will discuss these programs which enable the GPU to deliver incredibly immersive 3D gaming and responsive, complex user interfaces. Additionally, all of the above mentioned advanced graphics that are enabled by leading GPU technology require more device power. The panel will address new GPU architecture which performs more efficiently than predecessors. By using less power for the same workload to deliver advanced visuals, users can keep playing, watching and enjoying longer on mobile devices. Beyond what is possible today, industry experts on this panel will explore where mobile graphics are headed and discuss their companies' respective visions for the future of mobile graphics.

Objective To describe the epidemiology of 2009 A/H1N1 influenza in critically ill pregnant women.Design Population based cohort study.Setting All intensive care units in Australia and New Zealand.Participants All women with 2009 H1N1 influenza who were pregnant or recently post partum and admitted to an intensive care unit in Australia or New Zealand between 1 June and 31 August 2009.Main outcome measures Maternal and neonatal mortality and morbidity.Results 64 pregnant or postpartum women admitted to an intensive care unit had confirmed 2009 H1N1 influenza. Compared with non-pregnant women of childbearing age, pregnant or postpartum women with 2009 H1N1 influenza were at increased risk of admission to an intensive care unit (relative risk 7.4, 95% confidence interval 5.5 to 10.0). This risk was 13-fold greater (13.2, 9.6 to 18.3) for women at 20 or more weeks' gestation. At the time of admission to an intensive care unit, 22 women (34%) were post partum and two had miscarried. 14 women (22%) gave birth during their stay in intensive care and 26 (41%) were discharged from an intensive care unit with ongoing pregnancy. All subsequently delivered. 44 women (69%) were mechanically ventilated. Of these, nine (14%) were treated with extracorporeal membrane oxygenation. Seven women (11%) died. Of 60 births after 20 weeks' gestation, four were stillbirths and three were infant deaths. 22 (39%) of the liveborn babies were preterm and 32 (57%) were admitted to a neonatal intensive care unit. Of 20 babies tested, two were positive for the 2009 H1N1 virus.Conclusions Pregnancy is a risk factor for critical illness related to 2009 H1N1 influenza, which causes maternal and neonatal morbidity and mortality.

BACKGROUND:The optimal target range for blood glucose in critically ill patients remains unclear.METHODS:Within 24 hours after admission to an intensive care unit (ICU), adults who were expected to require treatment in the ICU on 3 or more consecutive days were randomly assigned to undergo either intensive glucose control, with a target blood glucose range of 81 to 108 mg per deciliter (4.5 to 6.0 mmol per liter), or conventional glucose control, with a target of 180 mg or less per deciliter (10.0 mmol or less per liter). We defined the primary end point as death from any cause within 90 days after randomization.RESULTS:Of the 6104 patients who underwent randomization, 3054 were assigned to undergo intensive control and 3050 to undergo conventional control; data with regard to the primary outcome at day 90 were available for 3010 and 3012 patients, respectively. The two groups had similar characteristics at baseline. A total of 829 patients (27.5%) in the intensive-control group and 751 (24.9%) in the conventional-control group died (odds ratio for intensive control, 1.14; 95% confidence interval, 1.02 to 1.28; P=0.02). The treatment effect did not differ significantly between operative (surgical) patients and nonoperative (medical) patients (odds ratio for death in the intensive-control group, 1.31 and 1.07, respectively; P=0.10). Severe hypoglycemia (blood glucose level, < or = 40 mg per deciliter [2.2 mmol per liter]) was reported in 206 of 3016 patients (6.8%) in the intensive-control group and 15 of 3014 (0.5%) in the conventional-control group (P<0.001). There was no significant difference between the two treatment groups in the median number of days in the ICU (P=0.84) or hospital (P=0.86) or the median number of days of mechanical ventilation (P=0.56) or renal-replacement therapy (P=0.39).CONCLUSIONS:In this large, international, randomized trial, we found that intensive glucose control increased mortality among adults in the ICU: a blood glucose target of 180 mg or less per deciliter resulted in lower mortality than did a target of 81 to 108 mg per deciliter. (ClinicalTrials.gov number, NCT00220987.)

Foodborne diseases remain an important public health problem in the United States. The Foodborne Diseases Active Surveillance Network (FoodNet) of CDC's Emerging Infections Program collects data from 10 U.S. states on diseases caused by enteric pathogens transmitted commonly through food. FoodNet is an active, population-based surveillance system for these laboratory-confirmed infections. This report describes preliminary surveillance data for 2008 and trends since 1996. In 2008, the estimated incidence of infections caused by Campylobacter, Cryptosporidium, Cyclospora, Listeria, Shiga toxin-producing Escherichia coli (STEC) O157, Salmonella, Shigella, Vibrio, and Yersinia did not change significantly when compared with the preceding 3 years. For most infections, incidence was highest among children aged <4 years, whereas the percentage of persons hospitalized and the case fatality rate were highest among persons aged >/=50 years. None of the Healthy People 2010 targets for reduction of foodborne pathogens (objective 10-1) were reached in 2008. The lack of recent progress points to gaps in the current food safety system and the need to continue to develop and evaluate food safety practices as food moves from the farm to the table.

The modern graphics processing unit (GPU) is the result of 40 years of evolution of hardware to accelerate graphics processing operations. It represents the convergence of support for multiple market segments: computer-aided design, medical imaging, digital content creation, document and presentation applications, and entertainment applications. The exceptional performance characteristics of the GPU make it an attractive target for other application domains. We examine some of this evolution, look at the structure of a modern GPU, and discuss how graphics processing exploits this structure and how nongraphical applications can take advantage of this capability. We discuss some of the technical and market issues around broader adoption of this technology.